A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

NCT02657551 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Cancer

Interventions

DRUG: Regorafenib

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]